These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 22990088)

  • 1. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Med Decis Making; 2012; 32(5):733-43. PubMed ID: 22990088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2.
    Roberts M; Russell LB; Paltiel AD; Chambers M; McEwan P; Krahn M;
    Med Decis Making; 2012; 32(5):678-89. PubMed ID: 22990083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.
    Roberts M; Russell LB; Paltiel AD; Chambers M; McEwan P; Krahn M;
    Value Health; 2012; 15(6):804-11. PubMed ID: 22999129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.
    Caro JJ; Briggs AH; Siebert U; Kuntz KM;
    Med Decis Making; 2012; 32(5):667-77. PubMed ID: 22990082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
    Caro JJ; Briggs AH; Siebert U; Kuntz KM;
    Value Health; 2012; 15(6):796-803. PubMed ID: 22999128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
    Weinstein MC; O'Brien B; Hornberger J; Jackson J; Johannesson M; McCabe C; Luce BR;
    Value Health; 2003; 6(1):9-17. PubMed ID: 12535234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).
    Willis M; Johansen P; Nilsson A; Asseburg C
    Pharmacoeconomics; 2017 Mar; 35(3):375-396. PubMed ID: 27838913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4.
    Karnon J; Stahl J; Brennan A; Caro JJ; Mar J; Möller J
    Med Decis Making; 2012; 32(5):701-11. PubMed ID: 22990085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting Quality of Discrete Event Simulations in Healthcare-Results From a Generic Reporting Checklist.
    Zhang X; Lhachimi SK; Rogowski WH
    Value Health; 2020 Apr; 23(4):506-514. PubMed ID: 32327168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4.
    Karnon J; Stahl J; Brennan A; Caro JJ; Mar J; Möller J;
    Value Health; 2012; 15(6):821-7. PubMed ID: 22999131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
    Kent S; Becker F; Feenstra T; Tran-Duy A; Schlackow I; Tew M; Zhang P; Ye W; Lizheng S; Herman W; McEwan P; Schramm W; Gray A; Leal J; Lamotte M; Willis M; Palmer AJ; Clarke P
    Pharmacoeconomics; 2019 Nov; 37(11):1305-1312. PubMed ID: 31347104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.
    Jahn B; Rochau U; Kurzthaler C; Paulden M; Kluibenschädl M; Arvandi M; Kühne F; Goehler A; Krahn MD; Siebert U
    Med Decis Making; 2016 Apr; 36(3):375-90. PubMed ID: 26476865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
    Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
    Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
    Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.